Tigenix NV (NASDAQ:TIG) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Analysts have set a one year consensus target price of $28.50 for the company, according to Zacks. Zacks has also assigned Tigenix an industry rank of 104 out of 265 based on the ratings given to its competitors.

TIG has been the topic of a number of recent research reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $30.00 price objective (up from $22.00) on shares of Tigenix in a research note on Wednesday, September 20th. BidaskClub lowered shares of Tigenix from a “hold” rating to a “sell” rating in a research note on Friday, October 27th. Finally, Zacks Investment Research lowered shares of Tigenix from a “hold” rating to a “sell” rating in a research note on Saturday, October 21st.

An institutional investor recently bought a new position in Tigenix stock. EAM Investors LLC purchased a new stake in shares of Tigenix NV (NASDAQ:TIG) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned approximately 1.20% of Tigenix at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.31% of the company’s stock.

Shares of Tigenix (NASDAQ:TIG) traded up $0.30 during midday trading on Tuesday, reaching $22.70. 15,600 shares of the company traded hands, compared to its average volume of 9,635. Tigenix has a fifty-two week low of $10.77 and a fifty-two week high of $25.72. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.36 and a current ratio of 1.37.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/05/analysts-set-28-50-target-price-for-tigenix-nv-tig.html.

Tigenix Company Profile

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Get a free copy of the Zacks research report on Tigenix (TIG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tigenix NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tigenix NV and related companies with MarketBeat.com's FREE daily email newsletter.